Hope for the youngest: drug trial aims to protect Babies' kidneys
NCT ID NCT04786574
Summary
This study aimed to see if a drug called tolvaptan could help babies with a rare, serious genetic kidney disease (ARPKD) by delaying the need for dialysis or transplant. It planned to give the drug to infants under 12 weeks old for two years and track their kidney health. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.